Identification and pre-clinical testing of a reversible cathepsin protease inhibitor reveals anti-tumor efficacy in a pancreatic cancer model.
about
Decreased expression of APAF-1 and increased expression of cathepsin B in invasive pituitary adenomaDetection of protease activities by flash chronopotentiometry using a reversible polycation-sensitive polymeric membrane electrode.Autophagy-Regulated ROS from Xanthine Oxidase Acts as an Early Effector for Triggering Late Mitochondria-Dependent Apoptosis in Cathepsin S-Targeted Tumor Cells.Monocyte-derived macrophage assisted breast cancer cell invasion as a personalized, predictive metric to score metastatic risk.Cathepsin L targeting in cancer treatment.IκB Kinase ε expression in pancreatic ductal adenocarcinomaCombined deletion of cathepsin protease family members reveals compensatory mechanisms in cancerSynthesis and biochemical evaluation of benzoylbenzophenone thiosemicarbazone analogues as potent and selective inhibitors of cathepsin L.Cathepsin S inhibitors: 2004-2010.Cathepsin B: multiple roles in cancer.Metastasis review: from bench to bedside.Cathepsins in digestive cancers.The feasibility of enzyme targeted activation for amino acid/dipeptide monoester prodrugs of floxuridine; cathepsin D as a potential targeted enzyme.STAT3 and STAT6 Signaling Pathways Synergize to Promote Cathepsin Secretion from Macrophages via IRE1α Activation.A novel cysteine cathepsin inhibitor yields macrophage cell death and mammary tumor regression.
P2860
Q34783764-2B5DAB40-4994-406D-81D8-DFD06CD09A64Q35074826-1135D989-CF47-49D6-BB65-28A9BF2311ACQ35647588-1CCD2894-78A7-449D-8663-E4E7038DCE5BQ36039489-0D951B7E-34BB-4D43-A7EA-CF32AE054A94Q36218199-E7F4FAED-7700-4694-990A-7BABA4E3EAB9Q36280308-8FEDC287-EB43-4E24-B012-E81241568B46Q36480910-89BCDE9C-EF8A-44FB-B324-E85A3BB57BB9Q36775345-2FFCEDB4-4680-4378-AA12-B27DBF6BC57FQ37845839-8DE874CD-6CA0-4B5B-972F-B3E51AD8C886Q38200056-B8686339-2C23-4F0A-9F37-E231E0C8642CQ38237985-615102A7-977E-42DD-8468-E71D9D20E1BEQ39237735-611D3925-3225-44B9-9F3A-5F37D3F06BA3Q39373589-AE98C1E7-8B20-4518-8B2B-54BE632BD214Q41434747-8D80B495-8EA8-43DB-B5E6-3A866D8811B9Q46755359-F89E4624-DC0D-45AC-AD35-08DF39B965A0
P2860
Identification and pre-clinical testing of a reversible cathepsin protease inhibitor reveals anti-tumor efficacy in a pancreatic cancer model.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 May 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Identification and pre-clinica ...... in a pancreatic cancer model.
@en
Identification and pre-clinica ...... in a pancreatic cancer model.
@nl
type
label
Identification and pre-clinica ...... in a pancreatic cancer model.
@en
Identification and pre-clinica ...... in a pancreatic cancer model.
@nl
prefLabel
Identification and pre-clinica ...... in a pancreatic cancer model.
@en
Identification and pre-clinica ...... in a pancreatic cancer model.
@nl
P2093
P2860
P1433
P1476
Identification and pre-clinica ...... y in a pancreatic cancer model
@en
P2093
Benelita Tina Elie
Johanna A Joyce
Leslie J Holsinger
Stacie A Dalrymple
Vasilena Gocheva
P2860
P304
P356
10.1016/J.BIOCHI.2010.04.023
P50
P577
2010-05-04T00:00:00Z